Primary membranous nephropathy (pMN) is most commonly driven by autoantibodies to PLA2R (and less often THSD7A), with titers tracking disease activity and treatment response. At Southern Medical Supplies Limited (SMSL), we provide a complete pMN work-up including anti-PLA2R IgG (quantitative ELISA with optional IFA/BIOCHIP® confirmation), THSD7A antibodies, IgG subclasses (incl. IgG4), and PLA2R antigen detection on renal biopsy (IF/IHC) when available. We pair serology with nephrotic-syndrome profiling—urine protein (ACR/PCR or 24-hour), serum albumin, lipid panel, creatinine/eGFR, and complement (C3/C4)—plus differentials and rule-outs (anti-GBM, ANCA, hepatitis B/C, HIV, and malignancy screens as indicated). Our solutions span ELISA, immunofluorescence, immunoblot, immunohistochemistry, molecular, and clinical chemistry platforms sourced from our broad network of partners—EUROIMMUN, Ansh Labs, Randox, Streck, Bio-Rad, Abbott, Roche, Siemens Healthineers, Qiagen, bioMérieux, Cepheid, Werfen, Globe Scientific, ELGA LabWater, LW Scientific, Sebia, LTA SRL, Acrobiotech, MAKOL Innovacion Medica, Rayto Life and Analytical Sciences, Diazyme, Hardy’s Diagnostics, and Teco Diagnostics—delivering the sensitivity, specificity, and reproducibility clinicians need to confirm pMN, guide therapy, and monitor immunologic and clinical remission.